Strides Shasun has resumed limited production at its Cuddalore API plant in India following a fire last week that killed one worker.
The facility was temporarily closed by government authorities following a fire Nov. 16 at the facility's new production block that resulted in one death and the injury of a second worker, in-PharmaTechnologist reported. The company didn't expect the suspension of production to have a material effect on revenues.
"The Cuddalore facility has been permitted to resume operations in all manufacturing production blocks except the new production block," the company told the publication.
The cause of the blaze is under investigation.
The facility, which was a Shasun operation prior to the Strides Shasun merger earlier this month, passed a World Health Organization inspection in 2012 that allowed for the organization's approval for the production of cycloserine used to treat tuberculosis. The plant also manufactures APIs used in ulcer medications and other generics.
- read the in-PharmaTechnologist story